News brief
On 2026-04-02, according to Xiniu Data, Xellar Biosystems completed Series A financing, raising RMB 200 million. Investors were lead investor Guoshouguquan, participating investor Jingtai Holdings, participating investor Yayi Capital, participating investor Junlian Capital. The company is an AI drug discovery platform.
Connected profiles
Explore
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2026年4月2日，据烯牛数据报道，Xellar Biosystems完成A轮融资，金额2亿人民币。投资方为国寿股权领投、晶泰控股、雅亿资本、君联资本跟投。该公司为AI药物发现平台。